This paper is in the following e-collection/theme issue:

Grant Proposals (eHealth, funded) (80)

Published on in Vol 5, No 4 (2016): Oct-Dec

Development of a Web-Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS-Hemo): Study Protocol

Development of a Web-Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS-Hemo): Study Protocol

Development of a Web-Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS-Hemo): Study Protocol

Authors of this article:

Alfonso Iorio1, 2 Author Orcid Image ;   Arun Keepanasseril1 Author Orcid Image ;   Gary Foster3, 4 Author Orcid Image ;   Tamara Navarro-Ruan1 Author Orcid Image ;   Alanna McEneny-King5 Author Orcid Image ;   Andrea N Edginton5 Author Orcid Image ;   Lehana Thabane3, 4 Author Orcid Image
Article Authors Cited by (86) Tweetations (2) Metrics

Journals

  1. Iorio A. Using pharmacokinetics to individualize hemophilia therapy. Hematology 2017;2017(1):595 View
  2. Pouplard C, Sattler L, Ryman A, Eschwege V, De Maistre E, Flaujac C, Szymezak J, Grand F, Repesse Y, Galinat H, Donnard M, Ternisien C, Iorio A, Chelle P, Jeanpierre E. Multicentre pharmacokinetic evaluation of rFVIII‐Fc (efmoroctocog alfa) in a real life and comparison with non‐extended half‐life FVIII concentrates. Haemophilia 2020;26(2):282 View
  3. Croteau S, Callaghan M, Davis J, Dunn A, Guerrera M, Khan O, Neufeld E, Raffini L, Recht M, Wang M, Iorio A. Focusing in on use of pharmacokinetic profiles in routine hemophilia care. Research and Practice in Thrombosis and Haemostasis 2018;2(3):607 View
  4. Castaman G, Linari S. Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A. Expert Opinion on Drug Metabolism & Toxicology 2018;14(2):143 View
  5. Gringeri A, Steinitz-Trost K, Doralt J. Current and future approaches to overcoming the challenges of hemophilia treatment personalization. Expert Opinion on Orphan Drugs 2017;5(7):589 View
  6. Stoffman J, Andersson N, Branchford B, Batt K, D’Oiron R, Escuriola Ettingshausen C, Hart D, Jiménez Yuste V, Kavakli K, Mancuso M, Nogami K, Ramírez C, Wu R. Common themes and challenges in hemophilia care: a multinational perspective. Hematology 2019;24(1):39 View
  7. Pasca S, Zanon E. Savings without changing: How to use the MyPKfit® device to improve treatment strategies in a cohort of patients with haemophilia A. Thrombosis Research 2019;183:1 View
  8. Calatayud J, Pérez-Alenda S, Carrasco J, Cruz-Montecinos C, Andersen L, Bonanad S, Querol F, Megías-Vericat J, Casaña J. Safety and Effectiveness of Progressive Moderate-to-Vigorous Intensity Elastic Resistance Training on Physical Function and Pain in People With Hemophilia. Physical Therapy 2020;100(9):1632 View
  9. Croteau S. Evolving Complexity in Hemophilia Management. Pediatric Clinics of North America 2018;65(3):407 View
  10. Yu J, Iorio A, Edginton A, Ahuja S, Álvarez Román M, Arrieta M, Arola M, Barillari G, Balasa V, Belletrutti M, Berrueco Moreno R, Beurrier P, Bidlingmaier C, Blanchette V, Blatny J, Bonanad S, Brose K, Brown D, Byant P, Canaro M, Carvalho M, Catarino C, Chitlur M, Cockrell E, Chowdary P, Cnossen M, Collins P, Coppens M, Croteau S, Cultrera D, de Cristofaro R, de Raucourt E, Desprez D, Dunn A, El‐Ekiabi M, Faganel Kotnik B, Fischer K, Frotscher B, Garbiero S, Garrido Ruiz R, Gill J, Gomez del Castillo C, Gottstein S, Lassandro G, Giordano P, Hart D, Hegemann I, Hermans C, Hua B, Hwang N, Jackson S, James P, Katsarou O, Kavakli K, Kempton C, Kentouche K, Khan O, Kobelt R, Kruse‐Jarres R, Laane E, Larson E, Lassila R, Lee A, Poon M, Lissick J, Langstrom S, Mahlangu J, Makris M, Marchesini E, Mateo J, Marco Vera P, Martorell M, Matsushita T, McCrae S, Mignot‐Castellano E, Montcrieff C, Maes P, Mondelars V, Bekart M, Mora E, Cristóbal Morales J, Mourey G, Bertrand M, Napolitano M, Siragusa S, Negrier C, Neme D, Niinimaki R, Oldenburg J, Albert T, Ornstein D, Ozelo M, Panetta J, Neufeld E, P'Ng S, Peerlinck K, Pollio B, Pouplard C, Gruel Y, Prezotti A, Price V, Primacakti F, Puyade M, Radossi P, Raffini L, Ragni M, Rangarajan S, Reding M, Reid R, Restrepo J, Ramirez J, Recht M, Rodriguez Lopez M, Ruiz‐Sàez A, Saleh M, Shapiro A, Sharathkumar A, Selmeczi A, Simpson M, Singleton T, Cruz M, Soto V, Steele M, Streif W, Sun H, Ritchie B, Sun J, Feng X, Suzuki T, Nagao A, Takemoto C, Tapp H, Teitel J, Tinmouth A, Thornburg C, Tosseto A, Turnstall O, Vezina C, Warren B, Wheeler A, Wilches Gutierrez J, Wu J, Wynn T, Yang R, Young G, Zanon E, Zupan I. Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. Research and Practice in Thrombosis and Haemostasis 2019;3(3):528 View
  11. Escobar M, Santagostino E, Mancuso M, Coppens M, Balasa V, Taylor J, Iorio A, Negrier C. Switching patients in the age of long-acting recombinant products?. Expert Review of Hematology 2019;12(sup1):1 View
  12. Chelle P, Yeung C, Croteau S, Lissick J, Balasa V, Ashburner C, Park Y, Bonanad S, Megías-Vericat J, Nagao A, Wynn T, Corrales-Medina F, Tran H, Sharathkumar A, Chitlur M, Sarmiento S, Edginton A, Iorio A. Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup. Clinical Pharmacokinetics 2020;59(2):245 View
  13. Ragni M, Croteau S, Morfini M, Cnossen M, Iorio A. Pharmacokinetics and the transition to extended half‐life factor concentrates: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis 2018;16(7):1437 View
  14. McEneny-King A, Chelle P, Iorio A, Edginton A. The effect of unmeasurable endogenous plasma factor activity levels on factor VIII dosing in patients with severe hemophilia A. Thrombosis Research 2018;170:53 View
  15. Nagao A, Yeung C, Germini F, Suzuki T. Clinical outcomes in hemophilia A patients undergoing tailoring of prophylaxis based on population-based pharmacokinetic dosing. Thrombosis Research 2019;173:79 View
  16. Chelle P, Yeung C, Bonanad S, Morales Muñoz J, Ozelo M, Megías Vericat J, Iorio A, Spears J, Mir R, Edginton A. Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients. Journal of Pharmacokinetics and Pharmacodynamics 2019;46(5):427 View
  17. Allard Q, Djerada Z, Pouplard C, Repessé Y, Desprez D, Galinat H, Frotscher B, Berger C, Harroche A, Ryman A, Flaujac C, Chamouni P, Guillet B, Volot F, Szymezak J, Nguyen P, Cazaubon Y. Real Life Population Pharmacokinetics Modelling of Eight Factors VIII in Patients with Severe Haemophilia A: Is It Always Relevant to Switch to an Extended Half-Life?. Pharmaceutics 2020;12(4):380 View
  18. Kremer Hovinga I, Schutgens R, van der Valk P, van Vulpen L, Mauser‐Bunschoten E, Fischer K. Continuous infusion of extended half‐life factor VIII (efmoroctocog alpha) for surgery in severe haemophilia A. Haemophilia 2018;24(4) View
  19. Morfini M, Farrugia A. Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia. Expert Review of Hematology 2019;12(10):883 View
  20. Solms A, Iorio A, Ahsman M, Vis P, Shah A, Berntorp E, Garmann D. Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach. Clinical Pharmacokinetics 2020;59(5):605 View
  21. Pasca S, Milan M, Sarolo L, Zanon E. PK-driven prophylaxis versus standard prophylaxis: When a tailored treatment may be a real and achievable cost-saving approach in children with severe hemophilia A. Thrombosis Research 2017;157:58 View
  22. Iorio A, Fischer K, Blanchette V, Rangarajan S, Young G, Morfini M. Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates. Thrombosis and Haemostasis 2017;117(06):1023 View
  23. Warren B, Jacobson L, Kempton C, Buchanan G, Recht M, Brown D, Leissinger C, Shapiro A, Abshire T, Manco‐Johnson M. Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes. Haemophilia 2019;25(5):867 View
  24. Croteau S, Wheeler A, Khan O, Haley K, Borst A, Lattimore S, Yeung C, Iorio A. Pharmacokinetic‐tailored approach to hemophilia prophylaxis: Medical decision making and outcomes. Research and Practice in Thrombosis and Haemostasis 2020;4(2):326 View
  25. Gupta S, Shapiro A. Optimizing bleed prevention throughout the lifespan: Womb to Tomb. Haemophilia 2018;24(S6):76 View
  26. Hermans C. Guidelines for the prophylaxis of haemophilia A and B: new horizons and ambitions. British Journal of Haematology 2020;190(5):643 View
  27. Lissitchkov T, Klukowska A, Pasi J, Kessler C, Klamroth R, Liesner R, Belyanskaya L, Walter O, Knaub S, Bichler J, Jansen M, Oldenburg J. Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program. Therapeutic Advances in Hematology 2019;10 View
  28. Klukowska A, Komrska V, Vdovin V, Zozulya N, Lissitchkov T, Oldenburg J, Ettingshausen C. octanate®: over 20 years of clinical experience in overcoming challenges in haemophilia A treatment. Therapeutic Advances in Hematology 2020;11 View
  29. Berntorp E. If you know you will also see: population pharmacokinetics is the way to personalize and optimize prophylaxis in hemophilia. Journal of Thrombosis and Haemostasis 2017;15(6):1103 View
  30. Carcao M, Chelle P, Clarke E, Kim L, Tiseo L, Morfini M, Hossain T, Rand M, Brown C, Edginton A, Lillicrap D, Iorio A, Blanchette V. Comparative pharmacokinetics of two extended half‐life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?. Journal of Thrombosis and Haemostasis 2019;17(7):1085 View
  31. de Morais Costa N, Costa Í, Guimarães T, de Souza H, Casaretto E, de Medeiros T, Barbosa S, Matos A, Oliveira E, Camelo R. North‐eastern Brazilian recommendations for the nurse professional role on the pharmacokinetic‐assisted prophylaxis individualization for haemophilia A. Haemophilia 2020;26(3) View
  32. Hajducek D, Chelle P, Hermans C, Iorio A, McEneny‐King A, Yu J, Edginton A. Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS‐Hemo project. Haemophilia 2020;26(3):384 View
  33. Morfini M. The History of Clotting Factor Concentrates Pharmacokinetics. Journal of Clinical Medicine 2017;6(3):35 View
  34. Dargaud Y, Delavenne X, Hart D, Meunier S, Mismetti P. Individualized PK‐based prophylaxis in severe haemophilia. Haemophilia 2018;24(S2):3 View
  35. Delavenne X, Dargaud Y, Ollier E, Négrier C. Dose tailoring of human cell line‐derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A. British Journal of Clinical Pharmacology 2019;85(4):771 View
  36. Iorio A, Blanchette V, Blatny J, Collins P, Fischer K, Neufeld E. Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis 2017;15(12):2461 View
  37. Iorio A, Edginton A, Blanchette V, Blatny J, Boban A, Cnossen M, Collins P, Croteau S, Fischer K, Hart D, Ito S, Korth‐Bradley J, Lethagen S, Lillicrap D, Makris M, Mathôt R, Morfini M, Neufeld E, Spears J. Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. Research and Practice in Thrombosis and Haemostasis 2018;2(3):535 View
  38. Megías-Vericat J, Bonanad S, Haya S, Cid A, Marqués M, Monte E, Pérez-Alenda S, Bosch P, Querol F, Poveda J. Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A. Thrombosis Research 2019;174:151 View
  39. Chowdary P. Extended half-life recombinant products in haemophilia clinical practice – Expectations, opportunities and challenges. Thrombosis Research 2020;196:609 View
  40. Abrantes J, Solms A, Garmann D, Nielsen E, Jönsson S, Karlsson M. Bayesian Forecasting Utilizing Bleeding Information to Support Dose Individualization of Factor VIII. CPT: Pharmacometrics & Systems Pharmacology 2019;8(12):894 View
  41. Calatayud J, Pérez-Alenda S, Carrasco J, Escriche A, Cruz-Montecinos C, Andersen L, Bonanad S, Querol F, Casaña J. Upper-Body Exercises With External Resistance Are Well Tolerated and Enhance Muscle Activity in People With Hemophilia. Physical Therapy 2019;99(4):411 View
  42. Rayment R, Chalmers E, Forsyth K, Gooding R, Kelly A, Shapiro S, Talks K, Tunstall O, Biss T. Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B. British Journal of Haematology 2020;190(5):684 View
  43. Kueppers F. PredictAAT: Accounting for Inflammation in the Diagnosis of Alpha 1 Antitrypsin Deficiency. COPD: Journal of Chronic Obstructive Pulmonary Disease 2020;17(6):619 View
  44. McEneny-King A, Chelle P, Henrard S, Hermans C, Iorio A, Edginton A. Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis. Pharmaceutics 2017;9(4):47 View
  45. Rodríguez López M, Megías Vericat J, Albo López C, Bonanad S. Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (albutrepenonacog alfa, rFIX-FP) in Spain. BMJ Case Reports 2020;13(10):e234142 View
  46. Croteau S, Wang M, Wheeler A. 2021 clinical trials update: Innovations in hemophilia therapy. American Journal of Hematology 2021;96(1):128 View
  47. Hermans C, Dolan G. Pharmacokinetics in routine haemophilia clinical practice: rationale and modalities—a practical review. Therapeutic Advances in Hematology 2020;11 View
  48. Strike K, Chan A, Iorio A, Maly M, Stratford P, Solomon P. Predictors of treatment adherence in patients with chronic disease using the Multidimensional Adherence Model: unique considerations for patients with haemophilia. The Journal of Haemophilia Practice 2020;7(1):92 View
  49. Traets M, Fischer K, Uitslager N, van der Valk P, Kremer Hovinga I, van Vulpen L, Schutgens R. Real-Life Pharmacokinetics of rFVIII-Fc and rFIX-Fc. TH Open 2020;04(04):e362 View
  50. Teitel J, Sholzberg M, Iorio A. Extended half‐life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products. Research and Practice in Thrombosis and Haemostasis 2021;5(2):349 View
  51. Di Minno A, Spadarella G, Esposito S, Mathew P, Di Minno G, Mannucci P. Perspective – The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021. Blood Reviews 2021;50:100849 View
  52. Astermark J, Olsson A, Chelle P, Täckström K, Walger M, Magnusson M, Iorio A. Comparison of single subject and population‐based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A. Haemophilia 2021;27(4):626 View
  53. Versloot O, Iserman E, Chelle P, Germini F, Edginton A, Schutgens R, Iorio A, Fischer K. Terminal half‐life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. Journal of Thrombosis and Haemostasis 2021;19(8):1896 View
  54. Stonebraker J, O'Mahony B, Noone D, Iorio A. Converting factor and nonfactor usage into a single metric to facilitate benchmarking the resources consumed for haemophilia care across jurisdictions and over time. Haemophilia 2021;27(5) View
  55. Ragni M. Optical or optimal conclusion: pharmacokinetic-guided dosing in haemophilia. The Lancet Haematology 2021;8(7):e469 View
  56. Álvarez Román M, Benítez O, Canaro M, López Fernández M, López Jaime F, Mateo Arranz J, Núñez R, Rodríguez López M, Sierra Aisa C, Jiménez-Yuste V. Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa. Expert Opinion on Biological Therapy 2021;21(9):1165 View
  57. Kun H, Xu W, Zhou M, Li X, Xu Z, Fang Y, Li C, Chen Z, Wu R. Pharmacokinetics and complementary evaluation system-based guidance on prophylaxis of paediatric patients with haemophilia A in China with Kovaltry: protocol of the LEAP study. BMJ Open 2021;11(7):e048432 View
  58. Megías-Vericat J, Bonanad S, Haya S, Cid A, Marqués M, Ferrada A, Monte-Boquet E, Pérez-Alenda S, Bosch P, Querol-Giner F, Poveda J. Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients. Thrombosis Research 2021;205:99 View
  59. Allen G, Du P, Khair K, Lee H, Ozelo M, Berthoz F, Windyga J. Addressing unmet needs in rare bleeding disorders: selected poster extracts of recent research in hemophilia A and von Willebrand disease presented at the 14th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) (Feb 3–5, 2021; virtual congress). Expert Review of Hematology 2021;14(sup1):1 View
  60. Kwan C, Bhatt M, Strike K, Decker K, Matino D, Chan A. Web-based Application for the Population Pharmacokinetic Service (WAPPS)'s impact on dosage selection: a single paediatric centre experience. The Journal of Haemophilia Practice 2021;8(1):80 View
  61. Megías-Vericat J, Bonanad Boix S, Berrueco Moreno R, Mingot-Castellano M, Rodríguez López M, Canaro Hirnyk M, Mateo Arranz J, Calvo Villas J, Haya Guaita S, Mesegué Medà M, López Jaime F, Albo-López C, Palomero-Massanet A, Vilalta Seto N, Leciñena I, Haro A, Poveda Andrés J. Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products. Thrombosis Research 2022;216:35 View
  62. Arvanitakis A, Holme P, Berntorp E, Astermark J. Clinical outcome and adherence rate in Scandinavian patients with intermediate‐intensity prophylaxis before and after the switch of standard half‐life FVIII products to BAY 81–8973. Haemophilia 2022;28(2):223 View
  63. Calatayud J, Pérez-Alenda S, Carrasco J, Escriche-Escuder A, Cruz-Montecinos C, Andersen L, Bonanad S, Querol F, Casaña J. Electromyographic and Safety Comparisons of Common Lower Limb Rehabilitation Exercises for People With Hemophilia. Physical Therapy 2020;100(1):116 View
  64. Versloot O, Iserman E, Chelle P, Germini F, Edginton A, Schutgens R, Iorio A, Fischer K. Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia. HemaSphere 2022;6(4):e694 View
  65. Bukkems L, Versloot O, Cnossen M, Jönsson S, Karlsson M, Mathôt R, Fischer K. Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A. Thrombosis and Haemostasis 2023;123(03):317 View
  66. Singkham N, Punyawudho B, Yu M, Cheng S, Chen S, Chang H, Chen C, Hsiao C, Hou J, Fang Y, Wang H, Lin J, Yu L, Chen Y. Influence of blood group and von Willebrand factor on population pharmacokinetics and dose individualization of recombinant factor VIII in Taiwanese patients with haemophilia A. Haemophilia 2022;28(2):230 View
  67. Núñez R, Álvarez-Román M, Bonanad S, González-Porras J, De La Corte-Rodriguez H, Berrueco R, Jiménez-Yuste V. The Limitations and Unmet Needs of the Five Cornerstones to Guarantee Lifelong Optimization of Prophylaxis in Hemophilia Patients. TH Open 2022;06(04):e365 View
  68. Primacakti F, Sari T, Gatot D, Sjakti H, Chozie N. Pharmacokinetic profile of children with haemophilia A receiving low‐dose FVIII prophylaxis in Indonesia: A single centre experience. Haemophilia 2022;28(5):720 View
  69. Nummi V, Lehtinen A, Iorio A, Szanto T, Lassila R. Switching from standard to extended half‐life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics. Haemophilia 2022;28(6) View
  70. Chang C, Chiou S, Weng T, Lin P, Lai S, Tsai C, Liu Y, Ku J, Liao Y, Tsai J, Hu S, Cheng C, Chen Y. Clinical Predictors and Prediction Models for rFVIII-Fc Half Life in Real-World People with Severe Hemophilia A. Journal of Clinical Medicine 2023;12(6):2207 View
  71. Charafi L, Campanella L, Shay B, Rabatin A, Hughes A, Kennerly-Shah J. Expanding Pharmacy Services to the Hemophilia Treatment Center. Hospital Pharmacy 2023;58(5):415 View
  72. Teng W, Kung C, Cheng M, Tsai J, Chang C. Intramural Hematoma of Gastrointestinal Tract in People with Hemophilia A and B. Journal of Clinical Medicine 2023;12(9):3093 View
  73. Hajducek D, Primacakti F, Chozie N, Mir R, McEneny-King A, Iorio A, Edginton A. Derivation of a Pharmacokinetic Model to Include a Plasma-Derived, von Willebrand Factor-Containing Factor VIII (Koate®-DVI) Concentrate and its Low-Dose Use. Plasmatology 2021;15 View
  74. Iorio A, Iserman E, Blanchette V, Dolan G, Escuriola Ettingshausen C, Hermans C, Negrier C, Oldenburg J, Reininger A, Rodriguez‐Merchan C, Spannagl M, Valentino L, Young G, Steinitz‐Trost K, Gringeri A. Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement. Haemophilia 2017;23(3) View
  75. Ay C, Kovacevic K, Kraemmer D, Schoergenhofer C, Gelbenegger G, Firbas C, Quehenberger P, Jilma-Stohlawetz P, Gilbert J, Zhu S, Beliveau M, Koenig F, Iorio A, Jilma B, Derhaschnig U, Pabinger I. The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A. Blood 2023;141(10):1147 View
  76. Schep S, Fischer K, Boes M, Schutgens R. No immunological changes after factor VIII product switch: An in depth analysis in haemophilia A patients. Haemophilia 2023;29(4):1039 View
  77. George C, Parikh S, Carter T, Mccosker J, Carlino S, Tran H. Evaluation of treatment and outcome for patients with haemophilia A and haemophilia B on extended half‐life (EHL) factor products: A 12‐month data analysis. Haemophilia 2023;29(5):1283 View
  78. Gultekin H, Kara T, Liu R, Lyu X, Li Y, Qin Z. AGILITY IN ADVERSITY: NAVIGATING THE SHIFT TO REMOTE WORK WITH AGILE METHODOLOGIES DURING COVID-19. International Journal of Research -GRANTHAALAYAH 2024;12(1) View
  79. Valke L, Cloesmeijer M, Mansouritorghabeh H, Barteling W, Blijlevens N, Cnossen M, Mathôt R, Schols S, van Heerde W. Pharmacokinetic–Pharmacodynamic Modelling in Hemophilia A: Relating Thrombin and Plasmin Generation to Factor VIII Activity After Administration of a VWF/FVIII Concentrate. European Journal of Drug Metabolism and Pharmacokinetics 2024;49(2):191 View
  80. Ljung R. Prophylactic Treatment of Children with Hemophilia in Sweden. Seminars in Thrombosis and Hemostasis 2024;50(05):714 View
  81. Nichele I, Carli G, Tosetto A. Tailored therapy with turoctocog alfa pegol according to patient’s lifestyle and hemorrhagic phenotype: from clinical trial to real-life. Bleeding, Thrombosis and Vascular Biology 2024;3(1) View
  82. Chelle P, Hajducek D, Thibaudeau K, Hobson N, Iorio A, Shapiro A, Edginton A. Development of a Plasminogen Population PK model supporting prophylactic replacement therapy for Plasminogen deficient patients within the WAPPS‐Hemo platform. Haemophilia 2024;30(4):988 View
  83. Hajducek D, Chelle P, Iorio A, Iserman E, Edginton A. Estimated prophylactic dose required to achieve 3% trough as a function of age and concentrate class in multi‐country severe WAPPS‐Hemo haemophilia patients. Haemophilia 2024;30(4):925 View
  84. Xue F, Dai J, Chen L, Liu W, Zhang H, Wu R, Sun J, Zhang X, Wu J, Zhao Y, Wang X, Yang R. Report on the diagnosis and treatment of hemophilia in China (Version 2024). LabMed Discovery 2024;1(1):100007 View
  85. Königs C, Motwani J, Jiménez-Yuste V, Blatný J. Teenagers and Adolescents with Hemophilia–Need for a Specific Approach. Journal of Clinical Medicine 2024;13(17):5121 View